Research programme: antibody-drug nanocell conjugates - EnGeneIC

Drug Profile

Research programme: antibody-drug nanocell conjugates - EnGeneIC

Alternative Names: EGFR VEDVsPNU

Latest Information Update: 16 Jan 2017

Price : $50

At a glance

  • Originator EnGeneIC
  • Class Drug conjugates; Immunoconjugates
  • Mechanism of Action DNA repair inhibitors; DNA topoisomerase I inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • On Fast track

    Fast track status is assigned by the US FDA so therapies with the potential to address unmet needs can move faster through development.

    No
  • New Molecular Entity No

Highest Development Phases

  • Preclinical Cancer

Most Recent Events

  • 10 Jan 2017 EngeneIC plans a phase I trial for Solid tumours (Late-stage disease, Inoperable/Unresectable, Metastatic disease) in Australia (ACTRN12617000037303p)
  • 20 May 2016 Preclinical trials in Cancer in Australia (IV)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top